anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Intervention: Stereotactic frameless brain tumour biopsy. A frameless STx biopsy is performed for each patient from the control group with the use of a neuronavigation system. The entry point, target and optimal biopsy trajectory are defined by the operator before the operation on the basis of the preoperatively obtained high-field MR images with the use of a neuronavigation workstation (Cranial 5, StealthStation Application Software, Medtronic Navigation, Louisville, CO, USA).
Valacyclovir hydrochloride is the hydrochloride salt of the L-valyl ester of the antiviral drug acyclovir.

Valacyclovir tablets, USP are for oral administration. Each tablet contains 556.2 mg or 1.112 grams of valacyclovir hydrochloride, USP (hydrous), which are equivalent to 500 mg or 1 gram of valacyclovir, on the anhydrous basis, respectively, and the inactive ingredients hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol and titanium dioxide. The white, film-coated tablets are printed with edible black ink which contains black iron oxide, propylene glycol and shellac glaze.

The chemical name of valacyclovir hydrochloride is L-valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl ester, monohydrochloride. It has the following structural formula: 

Valacyclovir hydrochloride, USP (hydrous) is a white to off-white powder with the molecular formula C13H20N6O4•HCl and a molecular weight of 360.80. The maximum solubility in water at 25°C is 174 mg/mL. The pkas for valacyclovir hydrochloride are 7.47 and 9.43.

Meets USP Dissolution Test 2.
Laser Assisted Liposuction with the LipoLife system. Each subject underwent laser assisted liposuction surgery w/wo facial fat grafting , using the LipoLifeTM system. Pre-surgery evaluation visit was carried out 1 week prior to the surgery. Follow up visits to evaluate safety and efficacy will take place at 1, 3 and 6 months after the surgery.
Subjects with untreated type 2 diabetes were studied using a randomized crossover design. The study began with an initial two-week observation period. Subjects then were randomly assigned to one arm of the study for 5 weeks. The carbohydrate:protein:fat ratio for the control diet is 55:15:30 whereas for the test diet it is 40:30:30. Following a five-week washout period, subjects were assigned to the other arm of the study. All meals were provided by the SDTU. A six-day rotating meal plan has been devised. At the beginning and end of the 5-week diet period, the subject was admitted to the SDTU (Special Diagnostic and Treatment Unit), was provided with the meals appropriate for the test or control arm of the study, and had blood drawn at various times during a 24-hour period. In addition to measurement of GH and IGF-1, IGF-binding proteins 1 and 3, ghrelin, and body composition were determined.
A method for preparing ferrite nanoparticles employing as directing agent an aldehyde or ketone of formula R 1 —(C═O)R 2  is provided. R 1  is a linear or branched, saturated or unsaturated carbon chain having a length between 1 and 13 carbon atoms, optionally substituted with an aromatic substituent. R 2  is selected from the group consisting of hydrogen, an aromatic ring and a linear or branched, saturated or unsaturated carbon chain having a length between 1 and 10 carbon atoms. When R 2  is hydrogen and R 1  is an unsaturated carbon chain substituted with an aromatic substituent, the aromatic substituent is located at position 3 or higher with respect to the carbonyl group —(C═O). When R 2  is hydrogen and R 1  is a saturated carbon chain substituted with an aromatic substituent, the aromatic substituent is located at position 2 or higher with respect to the carbonyl group —(C═O). When the aromatic substituent is located at position 2, the aromatic substituent is the sole substituent at position 2.
The invention provides an extraction method of radix glehniae polysaccharide. The extraction method includes the steps of radix glehniae smashing, hot water extraction, suction filtration, vacuum concentration, ethanol precipitation, drying and polysaccharide forming. Influence factors in the water extraction process of polysaccharide include extraction time, extraction temperature, the number of extraction times and material-water ratio in sequence. According to the optimal combination, the extraction time is 4 h, the extraction temperature is 90 DEG C, the number of extraction times is 3, and the material-water ratio is 1:30. After the volume of filter liquor becomes one fifth to one tenth the original volume through vacuum concentration, ethanol is added with the concentration of ethanol in the solution being 80%, standing is carried out for 8-10 h, centrifugation is carried out, and precipitate is taken with supernatant liquid discarded. The invention further discloses application of radix glehniae polysaccharide in preparing anti-oxidation drugs.
FIELD: clinical immunology. SUBSTANCE: invention provides strain of bacteria Brucella abortus 3143 in stable R form, which grows well on any nutrient medium used for growing brucellae. Strain manifests sufficient immunogenic activity. Preparation of serum requires only one immunization of producers (rabbits). EFFECT: simplified preparation of anti-brucellosis R serum. 2 ex
The placebo capsules are supplied as 950 mg capsules consisting of 475 mg corn oil and 475 mg soy oil. Both DHA and placebo are flavored with sweet orange flavoring and masking agents. Subjects will be instructed to take 2 capsules at breakfast and 2 capsules at dinner (with food). Subjects will take their first dose in the office to assure their ability to swallow the pills. Subjects will be dosed with the placebo for 12 weeks.
Eplerenone was non-genotoxic in a battery of assays including in vitro bacterial mutagenesis (Ames test in Salmonella spp. and E. Coli), in vitro mammalian cell mutagenesis (mouse lymphoma cells), in vitro chromosomal aberration (Chinese hamster ovary cells), in vivo rat bone marrow micronucleus formation, and in vivo/ex vivo unscheduled DNA synthesis in rat liver.

There was no drug-related tumor response in heterozygous P53 deficient mice when tested for 6 months at dosages up to 1000 mg/kg/day (systemic AUC exposures up to 9 times the exposure in humans receiving the 100 mg/day therapeutic dose). Statistically significant increases in benign thyroid tumors were observed after 2 years in both male and female rats when administered eplerenone 250 mg/kg/day (highest dose tested) and in male rats only at 75 mg/kg/day. These dosages provided systemic AUC exposures approximately 2 to 12 times higher than the average human therapeutic exposure at 100 mg/day. Repeat dose administration of eplerenone to rats increases the hepatic conjugation and clearance of thyroxin, which results in increased levels of TSH by a compensatory mechanism. Drugs that have produced thyroid tumors by this rodent-specific mechanism have not shown a similar effect in humans.

Male rats treated with eplerenone at 1000 mg/kg/day for 10 weeks (AUC 17 times that at the 100 mg/day human therapeutic dose) had decreased weights of seminal vesicles and epididymides and slightly decreased fertility. Dogs administered eplerenone at dosages of 15 mg/kg/day and higher (AUC 5 times that at the 100 mg/day human therapeutic dose) had dose-related prostate atrophy. The prostate atrophy was reversible after daily treatment for 1 year at 100 mg/kg/day. Dogs with prostate atrophy showed no decline in libido, sexual performance, or semen quality. Testicular weight and histology were not affected by eplerenone in any test animal species at any dosage.
Chronic kidney disease (CKD) is common, costly, and life-limiting, requiring dialysis and transplantation in advanced stages. Although effective guideline-based therapy exists, the asymptomatic nature of CKD together with low health literacy, adverse social determinants of health, unmet behavioral health needs, and primary care providers' (PCP) limited understanding of CKD result in defects in screening and diagnosis. Care is fragmented between PCPs and specialty nephrologists, with limited time, expertise, and resources to address systemic gaps. In this article, the authors define how they classified defects in care and report the current numbers of patients exposed to these defects, both nationally and in their health system Accountable Care Organization. They describe use of the health system's three-pillar leadership model (believing, belonging, and building) to empower providers to transform CKD care. Believing entailed engaging individuals to believe defects in CKD care could be eliminated and were a collective responsibility. Belonging fostered the creation of learning communities that broke down silos and encouraged open communication and collaboration between PCPs and nephrologists. Building involved constructing a fractal management infrastructure with transparent reporting and shared accountability, which would enable success in innovation and transformation. The result is proactive and relational CKD care organized around the patient's needs in University Hospitals Systems of Excellence. Systems of excellence combine multiple domains of expertise to promote best practice guidelines and integrate care throughout the system. The authors further describe a preliminary pilot of the CKD System of Excellence in primary care.
Process for make up and/or care of nails, comprises applying a layer of a first composition without pigment containing metallic oxide i.e. untreated on the surface, comprising at least a cyanoacrylate monomer (I), applying a layer of a second composition comprising a film forming polymer to the first layer and optionally applying a layer of the mixture of two compositions on the nail. Process for make up and/or care of nails, comprises applying a layer of a first composition without pigment containing metallic oxide i.e. untreated on the surface, comprising at least a cyanoacrylate monomer (I) of formula CN-C(CH 2)-COO-R, applying a layer of a second composition comprising a film forming polymer to the first layer and optionally applying a layer of the mixture of two composition on the nail. R : (alkoxy)alkyl, preferably 6-10C (alkoxy)alkyl. An independent claim is included for a make-up or care kit for nails comprising the first and second compositions.
Loss of estrogen receptor/progesterone receptor (ER/PR) in endometrial cancer (EC) is associated with tumor progression and poor outcomes. Elevated pretreatment cancer antigen 125 (CA 125) level is a risk factor for lymph node metastasis (LNM). We evaluated whether the combination of ER/PR expression and CA 125 level could be used as a biomarker to predict LNM. We retrospectively investigated patients with endometrioid EC who underwent complete staging surgery during January 2015 to December 2020. We analyzed ER/PR status using immunohistochemical staining, and quantified its expression using the sum of both ER/PR H -scores. Receiver operating characteristic curves were used to identify optimal cutoff values of H -score and CA 125 levels for predicting LNM. A nomogram for predicting LNM was constructed and validated by bootstrap resampling. In 396 patients, the optimal cutoff values of the ER/PR H -score and CA 125 were 407 (area under the receiver operating characteristic curve: 0.645, P =0.001) and 40 U/mL (area under the receiver operating characteristic curve: 0.762, P <0.001), respectively. Multivariate analysis showed that CA 125 ≥40 UmL (odds ratio: 10.02; 95% CI: 4.74-21.18) and ER/PR H -score <407 (odds ratio: 4.20; 95% CI: 1.55-11.32) were independent predictors. An LNM predictive nomogram was constructed using these 2 variables and our model yielded a negative predictive value and negative likelihood ratio of 98.3% and 0.14, respectively. ER/PR expression with pretreatment CA 125 levels can help estimate LNM risk and aid in decision-making regarding the need for lymphadenectomy in patients with endometrioid EC.
Participants in this arm will receive treatment C in period 1, treatment A in period 2 and treatment B in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
Group K IV to patients paracetamol 1 gr. It will be administered 3x1 + Dexketoprofen 50 mg 2x1. All patients will be administered 1mg/kg tramadol as rescue analgesic when NRS is 3 and above . 4mg IV to all patients with nausea and vomiting Ondansetron will be administered.
The influence of brain atrophy on sleep microstructure in Spinocerebellar Ataxias (SCAs) has not been extensively explored limiting the use of these sleep traits as surrogate biomarkers of neurodegeneration and clinical phenotype. The objective of the study is to explore the relationship between sleep microstructure and brain atrophy in SCA2 and its role in the clinical phenotype. Fourteen SCA2 mutation carriers (7 pre-manifest and 7 manifest subjects) underwent polysomnographic, structural MRI, and clinical assessments. Particularly, markers of REM and non-REM sleep microstructure, measures of cerebellar and brainstem atrophy, and clinical scores were analyzed through correlation and mediation analyses. The sleep spindle activity exhibited a negative correlation with the number of trials required to complete the verbal memory test (VMT), and a positive correlation with the cerebellar volume, but the significance of the latter correlation did not survive multiple testing corrections. However, the causal mediation analyses unveiled that sleep spindle activity significantly mediates the association between cerebellar atrophy and VMT performance. Regarding REM sleep, both phasic EMG activity and REM sleep without atonia exhibited significant associations with pontine atrophy and disease severity measures. However, they did not demonstrate a causal mediation effect between the atrophy measures and disease severity. Our study provides evidence about the association of the pontocerebellar atrophy with sleep microstructure in SCA2 offering insights into the cerebellar involvement in cognition via the control of the sleep spindle activity. Therefore, our findings may help to understand the disease pathogenesis and to better characterize sleep microstructure parameters as disease biomarkers.Clinical trial registration number (TRN): No applicable.
This is a Phase I, open-label trial in patients with metastatic or locally advanced solid tumor. There are three parts of the study: a dose-escalation part, a dose-expansion part, and a clinical expansion part. Dose escalation part is a standard "3+3" cohort design, for which 3 or 6 subjects will be enrolled at each dose level depending on the occurrence of dose-limiting toxicities (DLTs). Dose-expansion means that at least 10 subjects (included subjects of the dose-escalation part) will be selected in 2 - 3 dose levels to focus on the pharmacokinetics (PK) / pharmacodynamic (PD) features. After determination of the recommended dose for Phase II (RP2D), clinical expansion will be opened. Many more subjects will be invited to take part in the study and received the study drug at the RP2D. Additional purpose of the study is to find out whether the study drug has anti-tumor effects.
Negative magnetic resonance imaging (MRI) contrast agent and a positive contrast and signal substance are filled in one or more inner capsules (1) that are inserted into outer capsules (2,3) containing heavy substance that enables the capsule to sink through the stomach contents and reach the small intestine for diagnosing its migration and absorption visually. Negative MR1 contrast agent, e.g. abdoscan and a positive contrast and signal substance are filled in one or more capsule e.g. gelatin. These capsules are inserted as inner capsules into a common outer capsule which is provided with a heavy substance, e.g. barium sulfate in a sufficient amount such that specific gravity of the capsule is greater than the specific gravity of the stomach contents. As a result the capsule sinks in the stomach contents and reaches the small intestine without any time delay for diagnosing its migration and absorption visually. An independent claim is also included for the diagnostic apparatus designed to indicate the migration of a medicament through the digestive apparatus and its resorption during migration.
This research investigates brain structure and function in alcoholics compared to healthy nonalcoholic individuals. Alcoholics have shown impairments in cognitive processing of emotional signals. Some alcoholics are impaired in social skills, and many are unable to implement the strategies for interpersonal interactions that they recommend for themselves. For example, alcoholics have difficulty interpreting non-verbal emotional cues and recognizing facial expressions of emotion. When listening to sentences, alcoholics also have some difficulty judging emotional intonations and emotional content. In our research, we are trying to understand where in the brain these emotional behaviors take place, and whether or not the brain functions differently for alcoholic and nonalcoholic individuals. We present emotional words and pictures on a computer screen, and using MRI scans, we observe how the brain works when people purposefully respond to the words and pictures. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
The invention discloses a new castle disease virus chimeric multi-epitope recombinant polypeptide, a polypeptide vaccine and application thereof, wherein the amino acid sequence of the recombinant polypeptide is shown as SEQ ID NO. 05. The chimeric peptide vaccine is composed of a plurality of antigen surface groups from different virus strains, so that the chimeric peptide vaccine has stronger adaptability in coping with virus mutation, and further ensures that continuously and effectively resisting continuously evolving newcastle disease virus strains. In terms of the need for more effective and adaptable newcastle disease virus vaccines. The combination of epitopes from different viral proteins enhances the ability of the vaccine to induce a robust immune linkage response, thereby providing omnidirectional protection. The innovative method has remarkable effectiveness in preventing newcastle disease virus infection and reducing the risk of outbreak of poultry diseases through experiments, and provides wider protection for poultry.
Inborn errors of immunity lead to autoimmunity, inflammation, allergy, infection, and/or malignancy. Disease-causing JAK1 gain-of-function (GoF) mutations are considered exceedingly rare and have been identified in only four families. Here, we use forward and reverse genetics to identify 59 individuals harboring one of four heterozygous JAK1 variants. In vitro and ex vivo analysis of these variants revealed hyperactive baseline and cytokine-induced STAT phosphorylation and interferon-stimulated gene (ISG) levels compared with wild-type JAK1. A systematic review of electronic health records from the BioME Biobank revealed increased likelihood of clinical presentation with autoimmunity, atopy, colitis, and/or dermatitis in JAK1 variant-positive individuals. Finally, treatment of one affected patient with severe atopic dermatitis using the JAK1/JAK2-selective inhibitor, baricitinib, resulted in clinically significant improvement. These findings suggest that individually rare JAK1 GoF variants may underlie an emerging syndrome with more common presentations of autoimmune and inflammatory disease (JAACD syndrome). More broadly, individuals who present with such conditions may benefit from genetic testing for the presence of JAK1 GoF variants.
A lotion for the cold permanent waving of hair comprises an aqueous solution of a water-soluble mercaptan, e.g. thioglycollic acid, thioglycerol, thiosorbitol or mercaptopropionic acid, and ammonium carbonate and/or ammonium bicarbonate, the solution having been brought to a pH of 7.7 to 9.0 with ammonia.  The solution preferably contains 0.4-1.0 M mercaptan and sufficient carbonate to provide a CO3 molarity of between 0.25 and saturation.  The solution is preferably prepared by raising the pH of an aqueous thioglycollic acid solution to 5-7 by the addition of ammonia, then adding solid ammonium bicarbonate and raising the pH to 7.7-9.0 by the addition of ammonium hydroxide, thus converting some but not all of the bicarbonate to carbonate. Wetting agents, opacifiers and perfumes may be added.  Subsequent treatment of the hair with a neutralizer solution, e.g. aqueous potassium bromate, is effected.
The present invention relates to a method for preparing blood sugar-reducing, sleep-assisting and intestine-benefiting night milk with micron mulberry leaf powder, micron hawthorn powder, micron amber powder, micron picolinic acid chromium powder, fructo-oligosaccharide, micron pseudostellaria root powder and royal jelly dried powder. Raw material such as the micron mulberry leaf powder, the micron hawthorn powder, the micron amber powder, the micron picolinic acid chromium powder, the fructo-oligosaccharide, the micron pseudostellaria root powder, the royal jelly dried powder, etc. processed through high-technology airflow superfine grinding are added into different traditional milk liquid and combined and processed into the night milk. The night milk has the obvious function of reducing blood sugar and also has the effects of improving sleep quality, allaying fatigue, enhancing immunity, tranquilizing, improving eyesight, etc. The night milk can obtain scores of nutrient substances such as abundant protein, vitamins, mineral substances, active ferment, etc. and simultaneously has the functions of beautifying faces, keeping youthfulness, tranquilizing and reducing blood sugar because picolinic acid chromium which is extolled as a blood sugar reducing factor is added. Therefore, the present invention is a favorable method for preparing the night milk for protecting health and prolonging life, and the night milk has Chinese characteristics and is especially designed for middle-aged diabetics and old diabetics all over the world.
Emphysema in patients with chronic obstructive pulmonary disease (COPD) is characterized by progressive inflammation. Preclinical studies suggest that lung volume reduction surgery (LVRS) and mesenchymal stromal cell (MSC) treatment dampen inflammation. We investigated the effects of bone marrow-derived MSC (BM-MSC) and LVRS on circulating and pulmonary immune cell profiles in emphysema patients using mass cytometry. Blood and resected lung tissue were collected at the first LVRS (L1). Following 6-10 weeks of recovery, patients received a placebo or intravenous administration of 2 × 106 cells/kg bodyweight BM-MSC (n = 5 and n = 9, resp.) in week 3 and 4 before the second LVRS (L2), where blood and lung tissue were collected. Irrespective of BM-MSC or placebo treatment, proportions of circulating lymphocytes including central memory CD4 regulatory, effector memory CD8 and γδ T cells were higher, whereas myeloid cell percentages were lower in L2 compared to L1. In resected lung tissue, proportions of Treg (p = 0.0067) and anti-inflammatory CD163- macrophages (p = 0.0001) were increased in L2 compared to L1, while proportions of pro-inflammatory CD163+ macrophages were decreased (p = 0.0004). There were no effects of BM-MSC treatment on immune profiles in emphysema patients. However, we observed alterations in the circulating and pulmonary immune cells upon LVRS, suggesting the induction of anti-inflammatory responses potentially needed for repair processes.